<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357420</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-009</org_study_id>
    <secondary_id>2014-005623-27</secondary_id>
    <nct_id>NCT02357420</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis</brief_title>
  <official_title>A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin
      on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1
      and Type 2 diabetes mellitus and gastroparesis. Study drug (relamorelin and placebo) will be
      administered subcutaneously in a blinded fashion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2015</start_date>
  <completion_date type="Actual">June 9, 2016</completion_date>
  <primary_completion_date type="Actual">June 9, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Vomiting Episodes</measure>
    <time_frame>7 days prior to Day 1 for Baseline to 7 days prior to Week 12</time_frame>
    <description>Vomiting episodes were assessed via the Diabetic Gastroparesis Symptoms Severity Diary (DGSSD). The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of Diabetic Gastroparesis (DG) (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Each day, the participant recorded the number of vomiting episodes in the past 24 hours in the diary. Higher scores indicate more vomiting episodes. Weekly scores were averaged across the 12 weeks period. A negative change from Baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain)</measure>
    <time_frame>7 days prior to Day 1 for Baseline to 7 days prior to Week 12</time_frame>
    <description>The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of DG (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Severity of nausea, bloating and abdominal pain, were assessed on a numerical rating scale of 0 to 10, with 0 equating to &quot;no&quot; (symptom) and 10 equating to &quot;worst possible&quot; (symptom). Early satiety was assessed on a 5-item scale with 1 being &quot;Only 1 or 2 bites&quot; and 5 being &quot;All of a normal-sized meal&quot;; symptom severity scores for this item were reversed and normalized to a range 0 to 10 for the development of the DGSSD 4-symptom Composite Score. The DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal pain) range is 0 to 40. Higher scores indicate worse condition. Weekly scores were averaged across 12 weeks period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time</measure>
    <time_frame>Baseline (Day 1) to Week 12</time_frame>
    <description>GE was measured via the GEBT and was reported as a time to half (t1/2) of the theoretical total GE. GEBT is a non-radioactive stable isotope breath test intended for measurement of GE of solids in participants. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">393</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus Complications</condition>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Relamorelin 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relamorelin 30 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relamorelin 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relamorelin</intervention_name>
    <description>Double blind relamorelin was given subcutaneously BID for 12 weeks.</description>
    <arm_group_label>Relamorelin 10 μg</arm_group_label>
    <arm_group_label>Relamorelin 100 μg</arm_group_label>
    <arm_group_label>Relamorelin 30 μg</arm_group_label>
    <other_name>RM-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given subcutaneously for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM) with stable
             glycemic control and Hemoglobin A1c (HbA1c) ≤11% at screening.

          -  Diabetic gastroparesis (DG), defined as at least a 3-month history of symptoms
             suggestive of gastroparesis on an ongoing basis (e.g., vomiting, nausea, early
             satiety, bloating, or epigastric or abdominal pain).

          -  Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) score ≥2.6 at least once
             during the Screening Period (Visits 1-2).

          -  At least 2 vomiting episodes during the ~2 weeks prior to the first screening visit
             (Visit 1), as ascertained by patient history.

          -  Delayed Gastric Emptying (GE) confirmed at screening by abnormal Gastric Emptying
             Breath Test (GEBT), defined as GE half-time (t1/2) ≥79 minutes (the 80th percentile of
             normative data). At least 50% of patients enrolled will have a t1/2 ≥97 minutes (i.e.,
             the 95th percentile).

          -  Stable concomitant medications, defined as no changes in regimen for at least 2 weeks
             prior to Visit 2 (daily adjustments of insulin doses are permitted).

          -  No use of metoclopramide, erythromycin, domperidone, or other gastrointestinal (GI)
             motility agents, or anti-emetics for at least 2 weeks prior to Visit 2, and
             willingness to remain off these medications (except as used as part of
             protocol-specific rescue medication) during the course of the clinical trial.

          -  Body mass index &gt;18 kg/m2.

          -  If female, has a negative serum or urine pregnancy test and is not lactating. For
             females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and
             single-barrier method, or a double-barrier method of birth control must be used
             throughout the study. Female patients unable to bear children must have this
             documented in the electronic case report form (eCRF) (i.e., tubal ligation,
             hysterectomy, or post-menopausal [defined as a minimum of 1 year since the last
             menstrual period]). Post-menopausal status will be confirmed by measurement of
             follicle stimulating hormone (FSH).

          -  Able to provide written informed consent prior to any study procedures and willing and
             able to comply with study procedures.

        Additional inclusion criteria for randomization after the 2-week single-blind placebo
        run-in period:

          -  Compliance with the completion of the Diabetic Gastroparesis Symptom Severity Diary
             (DGSSD) and study drug injections, defined as approximately 80% diary completions and
             approximately 80% administration of injections, during the 2-week single-blind placebo
             run-in period. For those patients whose compliance is measured to be &lt;80%, the final
             decision to randomize a patient will be made by the Investigator and the Sponsor (or
             designee).

          -  At least one vomiting episode at any time during the 2-week single-blind placebo
             run-in period, as recorded in the DGSSD.

        Exclusion Criteria:

          -  Currently receiving parenteral feeding or presence of a nasogastric or other enteral
             tube [e.g., Percutaneous Endoscopic Gastrostomy (PEG) tube] for feeding or
             decompression.

          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker
             placement, vagotomy, or bariatric procedure. (A history of diagnostic endoscopy is not
             exclusionary.)

          -  History of pyloric injection of botulinum toxin within 6 months of screening.

          -  Patients with clinical suspicion of upper GI obstruction (e.g., peptic stricture) must
             have been evaluated per standard of care and obstruction ruled out before screening.

          -  Currently taking opiates, or expecting to use opiates during the course of the
             clinical trial.

          -  Currently taking Glucagon-like peptide-1 (GLP-1) agonists, Sodium-glucose
             co-transporter 2 (SGLT2) inhibitors or pramlintide.

          -  Allergic or intolerant of egg, wheat, milk, or algae, as these are components of the
             Gastric emptying breath test (GEBT) study meal. (Gluten-free crackers can be
             provided.)

          -  History of anorexia nervosa, binge-eating, or bulimia within 5 years of screening.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 × upper limit
             of normal (ULN) at Visit 1.

          -  History of intestinal malabsorption or pancreatic exocrine disease.

          -  Requires hemodialysis or has end-stage renal disease.

          -  History of human immunodeficiency virus (HIV) infection.

          -  Clinically significant neurologic or psychiatric disorders that are likely to impact
             compliance with protocol requirements.

          -  Poor venous access or inability to tolerate venipuncture.

          -  Participation in a clinical study within the 30 days prior to dosing in the present
             study.

          -  Any other reason that, in the Investigator's opinion, would confound proper
             interpretation of the study or expose a patient to unacceptable risk, including renal,
             hepatic or cardiopulmonary disease, or significant acute electrocardiogram (ECG)
             abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wieslaw Bochenek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialist of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sun Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adobe Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Family Medical Center</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Primary Care Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital‐ Office of Clinical trials</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APF Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Diabetes Associates, P.A.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance LLC</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Gastroenterology Associates, Ltd.</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America LA, LLC</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group, P.C. (Chevy Chase Clinical Research) Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center, PC‐Farmington Hills</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planters Clinic</name>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <zip>39150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials, Inc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions‐ Lexington OnSite Clinical Solutions, LLC</name>
      <address>
        <city>Lexington</city>
        <state>North Carolina</state>
        <zip>27292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrinology Consultants, P.C.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Health ‐ Dept of Gastroenterology Medical Center Blvd</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Leveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterology Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine of SayeBrook</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Specialists of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center &amp; Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Medical Research, LLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khan and Abbasi Research</name>
      <address>
        <city>Chester</city>
        <state>Virginia</state>
        <zip>23831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healing Hands of Virginia LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZainResearch, LLC</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme ‐ Universite Libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz und Diabeteszentrum Nordrhein Westfalen, Universitätsklinikum der Ruhr‐Universiät Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Ott Rabenauer Str.</name>
      <address>
        <city>Dippoldiswalde</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT‐TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Israelitisches Krankenhaus Orchideenstig</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Zentrum und Praxis Prof. Pfützner Parcusstr.</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus ‐ Inst. of Endocrinology, Diabetes, and Metabolism</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital Gastroenterology Dept</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorób Kostno‐Stawowych J. Badurski S.J. ul.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Witamed al.</name>
      <address>
        <city>Kielce</city>
        <zip>25-035</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski dr n.med. Malgorzata Saryusz‐Wolska ul.</name>
      <address>
        <city>Lodz</city>
        <zip>90-132</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Pulsmedica ul.</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO‐MED Centra Kliniczne</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badawcze Wspólczesnej Terapii ul.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-679</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-679</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Karolinska University Hospital Karolinska Universitetssjukhuset Gastro Centrum Medicine</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital Gastroenterology / Mag‐Tarmmottagningen ingang</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wansbeck General Hospital (Northumbria NHS Trust)</name>
      <address>
        <city>Ashington</city>
        <zip>NE63 9JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham University Hospital of North Durham Research and Development Directorate</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyne And Wear</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <results_first_submitted>July 1, 2019</results_first_submitted>
  <results_first_submitted_qc>July 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <disposition_first_submitted>February 16, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 15, 2016</disposition_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Delayed Gastric Emptying</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>Gastrointestinal Motility Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total 393 participants were randomized and received study treatment, and 334 participants completed the study. Five participants who received study drug but discontinued prematurely were summarized as completing the study because they fulfilled the Visit 8 (Week 12) assessments as per protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Relamorelin 10 μg</title>
          <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Relamorelin 30 μg</title>
          <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Relamorelin 100 μg</title>
          <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="81">1 participant from safety set did not enter FAS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92">3 participants who discontinued prematurely were included in completed as they fulfilled Visit 8.</participants>
                <participants group_id="P2" count="86">1 participant who discontinued prematurely was included in completed as he/she fulfilled Visit 8.</participants>
                <participants group_id="P3" count="93">1 participant who discontinued prematurely was included in completed as he/she fulfilled Visit 8.</participants>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn Consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set (SS) included all participants who were randomized and received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Relamorelin 10 μg</title>
          <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Relamorelin 30 μg</title>
          <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Relamorelin 100 μg</title>
          <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="393"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="11.9"/>
                    <measurement group_id="B2" value="59.3" spread="10.2"/>
                    <measurement group_id="B3" value="56.0" spread="11.7"/>
                    <measurement group_id="B4" value="57.1" spread="11.0"/>
                    <measurement group_id="B5" value="57.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Weekly Vomiting Episodes</title>
        <description>Vomiting episodes were assessed via the Diabetic Gastroparesis Symptoms Severity Diary (DGSSD). The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of Diabetic Gastroparesis (DG) (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Each day, the participant recorded the number of vomiting episodes in the past 24 hours in the diary. Higher scores indicate more vomiting episodes. Weekly scores were averaged across the 12 weeks period. A negative change from Baseline indicates improvement.</description>
        <time_frame>7 days prior to Day 1 for Baseline to 7 days prior to Week 12</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relamorelin 10 μg</title>
            <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Relamorelin 30 μg</title>
            <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Relamorelin 100 μg</title>
            <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Vomiting Episodes</title>
          <description>Vomiting episodes were assessed via the Diabetic Gastroparesis Symptoms Severity Diary (DGSSD). The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of Diabetic Gastroparesis (DG) (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Each day, the participant recorded the number of vomiting episodes in the past 24 hours in the diary. Higher scores indicate more vomiting episodes. Weekly scores were averaged across the 12 weeks period. A negative change from Baseline indicates improvement.</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
          <units>vomiting episodes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="6.0"/>
                    <measurement group_id="O2" value="7.7" spread="17.2"/>
                    <measurement group_id="O3" value="6.9" spread="10.3"/>
                    <measurement group_id="O4" value="4.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="5.8"/>
                    <measurement group_id="O2" value="-3.7" spread="12.5"/>
                    <measurement group_id="O3" value="-3.8" spread="7.6"/>
                    <measurement group_id="O4" value="-1.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Measures mixed effects model (MMRM)</method>
            <method_desc>MMRM analysis used treatment, week, treatment-by-week interaction as fixed factors and baseline values as the covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>MMRM</method>
            <method_desc>MMRM analysis used treatment, week, treatment-by-week interaction as fixed factors and baseline values as the covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>MMRM</method>
            <method_desc>MMRM analysis used treatment, week, treatment-by-week interaction as fixed factors and baseline values as the covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain)</title>
        <description>The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of DG (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Severity of nausea, bloating and abdominal pain, were assessed on a numerical rating scale of 0 to 10, with 0 equating to &quot;no&quot; (symptom) and 10 equating to &quot;worst possible&quot; (symptom). Early satiety was assessed on a 5-item scale with 1 being &quot;Only 1 or 2 bites&quot; and 5 being &quot;All of a normal-sized meal&quot;; symptom severity scores for this item were reversed and normalized to a range 0 to 10 for the development of the DGSSD 4-symptom Composite Score. The DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal pain) range is 0 to 40. Higher scores indicate worse condition. Weekly scores were averaged across 12 weeks period. A negative change from Baseline indicates improvement.</description>
        <time_frame>7 days prior to Day 1 for Baseline to 7 days prior to Week 12</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relamorelin 10 μg</title>
            <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Relamorelin 30 μg</title>
            <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Relamorelin 100 μg</title>
            <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain)</title>
          <description>The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of DG (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Severity of nausea, bloating and abdominal pain, were assessed on a numerical rating scale of 0 to 10, with 0 equating to &quot;no&quot; (symptom) and 10 equating to &quot;worst possible&quot; (symptom). Early satiety was assessed on a 5-item scale with 1 being &quot;Only 1 or 2 bites&quot; and 5 being &quot;All of a normal-sized meal&quot;; symptom severity scores for this item were reversed and normalized to a range 0 to 10 for the development of the DGSSD 4-symptom Composite Score. The DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal pain) range is 0 to 40. Higher scores indicate worse condition. Weekly scores were averaged across 12 weeks period. A negative change from Baseline indicates improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="6.7"/>
                    <measurement group_id="O2" value="21.8" spread="6.9"/>
                    <measurement group_id="O3" value="21.1" spread="6.0"/>
                    <measurement group_id="O4" value="22.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="8.1"/>
                    <measurement group_id="O2" value="-7.7" spread="7.8"/>
                    <measurement group_id="O3" value="-7.5" spread="7.4"/>
                    <measurement group_id="O4" value="-8.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time</title>
        <description>GE was measured via the GEBT and was reported as a time to half (t1/2) of the theoretical total GE. GEBT is a non-radioactive stable isotope breath test intended for measurement of GE of solids in participants. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 12</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relamorelin 10 μg</title>
            <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Relamorelin 30 μg</title>
            <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Relamorelin 100 μg</title>
            <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time</title>
          <description>GE was measured via the GEBT and was reported as a time to half (t1/2) of the theoretical total GE. GEBT is a non-radioactive stable isotope breath test intended for measurement of GE of solids in participants. A negative change from Baseline indicates improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment and provided at least 1 postbaseline primary efficacy measurement (DGSSD). Number analyzed is the number of participants with data available at the given time-point.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.1" spread="36.5"/>
                    <measurement group_id="O2" value="126.8" spread="37.6"/>
                    <measurement group_id="O3" value="128.6" spread="35.9"/>
                    <measurement group_id="O4" value="133.6" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="38.5"/>
                    <measurement group_id="O2" value="-12.7" spread="38.1"/>
                    <measurement group_id="O3" value="-12.8" spread="36.5"/>
                    <measurement group_id="O4" value="-13.6" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 98 days</time_frame>
      <desc>Safety set included all the participants who were randomized and received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo-matching relamorelin was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Relamorelin 10 μg</title>
          <description>Relamorelin 10 microgram (μg) was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Relamorelin 30 μg</title>
          <description>Relamorelin 30 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Relamorelin 100 μg</title>
          <description>Relamorelin 100 μg was administered SC by injection BID for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Median nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Traumatic hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

